New Guidelines for the Treatment of Cardiogenic Shock
The U.S. Food and Drug Administration (FDA) has determined Impella is safe and effective for its intended uses.
-
1,200+
Peer-reviewed clinical studies have published on Impella, including the PROTECT II randomized controlled trial
-
13
Clinical society guidelines include Impella heart pumps
-
330,000+
Patients have been treated with Impella heart pumps
DanGer Shock Results from Jacob Møller, M.D.
Jacob Møller, M.D., the principal investigator of the DanGer Shock trial, discusses study results he presented at the 2024 American College of Cardiology (ACC) Scientific Session in this interview with Abiomed's Chief Medical Officer Chuck Simonton, M.D.
For Interventional Cardiologists
Treat high-risk PCI, cardiogenic shock and right heart failure patients
For Cardiac and Vascular Surgeons
Escalate, stabilize and recover native organs with minimally-invasive surgical techniques
For Nurses
Use calculators, watch quick skills videos and learn patient management best practices
For Fellows
Advance your knowledge and develop skills to treat complex PCI patients
For Referring Providers
Are you caring for patients with heart disease? Learn more about how Impella heart pumps work, the benefits of Protected PCI with Impella and explore patient identification resources.
References
- Møller, J., et al. (2024). Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med.
NPS-1309